认知障碍的网络结构:从主观认知衰退到阿尔茨海默病
Giorgia Tosi1,2, Salvatore Nigro3, Daniele Urso3,4
1Human and Social Sciences Department, University of Salento, Lecce 73100, Italy.
概括
阿尔茨海默病重组认知功能,与主观认知衰退或轻度认知障碍不同. 这项研究使用探索性图形分析来揭示这些复杂的脑功能变化,超出了简单的性能下降.
科学领域:
- 神经科学是一个神经科学.
- 认知心理学 认知心理学
- 医疗成像医学成像
背景情况:
- 痴呆症的特点是认知能力下降,但认知功能的重组可能会提供更细致的理解.
- 探索图分析 (Exploratory Graph Analysis,简称EGA) 是一种分析认知功能之间的复杂关系的方法.
研究的目的:
- 使用EGA,研究阿尔茨海默病 (AD),轻度认知障碍 (MCI) 和主观认知衰退 (SCD) 中认知功能的结构重组.
- 探索认知架构如何在痴呆症的临床前和临床阶段发生变化.
主要方法:
- 将EGA应用于SCD,MCI和AD组中的638名个体的神经心理测试数据.
- 分析了各种认知领域之间的相互关系和分离模式.
主要成果:
- 阿尔茨海默病 (AD) 显示记忆得分与其他功能脱而出,并且减少了记忆子域内的相互关系.
- 主观认知衰退 (SCD) 呈现出分离的认知领域.
- 轻度认知障碍 (MCI) 呈现出不太稳定的,杂的认知模式.
结论:
- 与临床前阶段相比,阿尔茨海默氏症 (AD) 导致认知重组,以减少分成的架构.
- 痴呆症的认知功能变化涉及结构重组,不仅仅是表现下降.
- 这些发现对解释和利用临床环境中的神经心理测试有影响.
更多相关视频
相关概念视频
Alzheimer's Disease: Overview
462
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
462
Dementia
110
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
110
Cognitive Development During Adulthood
92
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
92
Alzheimer's Disease: Treatment
179
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
179
Amnesia
119
Amnesia is a condition marked by long-term memory loss, which impairs the ability to recall past events or create new memories.
The severity and duration of memory loss vary depending on the type and underlying cause. Amnesia is classified into two main types: retrograde and anterograde.
Retrograde amnesia is marked by the loss of memories formed before the onset of the condition. Patients may recall distant past events but often forget those occurring shortly before the incident.
Anterograde...
The severity and duration of memory loss vary depending on the type and underlying cause. Amnesia is classified into two main types: retrograde and anterograde.
Retrograde amnesia is marked by the loss of memories formed before the onset of the condition. Patients may recall distant past events but often forget those occurring shortly before the incident.
Anterograde...
119
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
120
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
120


